What kinds of disease biomarkers can MIP sensors detect?
MIP sensors can detect a wide range of biomarkers, from small molecules and peptides to large proteins and even volatile organic compounds in breath. For instance, a MIP sensor for the peptide ELPLYR, a biomarker for small-cell lung cancer, achieved a limit of quantitation of 78 ng/mL in blood and digested serum samples [1]. Another sensor detected phosphoenolpyruvate (PEP), a biomarker for acute lymphoblastic leukemia, with a limit of detection of 2.24 × 10⁻¹³ M in standard solutions and 1.56 × 10⁻¹³ M in human serum [3]. For viral infections, a MIP-based sensor detected the NS1 protein (a dengue fever biomarker) down to 0.3 ng/mL in human serum [4]. Even volatile biomarkers are within reach: a MIP sensor for isopropanol in exhaled breath, a potential diabetes marker, showed sensitivity up to 0.63 nm/%IPA [2]. This breadth—covering cancer, metabolic, neurological, and infectious disease markers—is a major strength of the technology.
How sensitive and selective are MIP sensors compared to traditional methods?
MIP sensors often match or exceed the performance of traditional antibody-based tests, especially in terms of sensitivity and cost. The lung cancer peptide sensor had a sensitivity of 166.51 Hz/mM, which was over five times higher than its non-imprinted counterpart [1]. The leukemia biomarker sensor achieved a detection limit in the sub-picomolar range (10⁻¹³ M), which is extraordinarily low [3]. For Alzheimer's disease, a MIP sensor detected amyloid β1-42 with a limit of detection of 0.14 ng/mL and showed minimal interference from the Tau protein [10]. Selectivity is also strong: the dengue sensor had recoveries of 95–97% in real human serum samples [4], and a pipecolic acid sensor (for neurological disorders) retained over 87% of its response after 28 days and showed high selectivity against similar amino acids [7]. These figures indicate that MIP sensors can be both highly sensitive and specific, often rivaling or surpassing conventional immunoassays.
What are the current limitations and challenges?
Despite promising lab results, MIP sensors face several hurdles before widespread clinical use. Many studies are still at the proof-of-concept stage, testing only a few samples or artificial fluids. For example, the lung cancer sensor was tested in artificial cerebrospinal fluid and blood spots, but not yet in a large clinical trial [1]. A 2025 review notes that challenges remain in translating MIP sensors from the lab to real-world diagnostics, including issues with scalability, batch-to-batch reproducibility, and performance in complex biological matrices like whole blood [5]. Another review from 2024 highlights that while MIP sensors are excellent for detecting volatile biomarkers in breath, commercialization is still limited by factors like sensor drift and the need for standardized protocols [9]. Additionally, some MIP sensors require careful optimization of the polymer film and template removal, which can be time-consuming [8]. So, while the technology is highly promising, it is not yet a routine clinical tool.
About These Sources
This answer is built on 10 peer-reviewed studies — published from 2021 to 2026, 8 from 2024 or later, 4 in Q1 journals, collectively cited 313 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 78 papers retrieved from a database of over 500 million.
Sources used in this answer
Design of Hyperporous Molecularly Imprinted Thin Films for Ultrasensitive Antibody-Free QCM Detection of a Small-Cell Lung Cancer Biomarker.
Developed a hyperporous MIP-based QCM sensor for the lung cancer biomarker ELPLYR, achieving a limit of quantitation of 78 ng/mL and detecting it in blood and serum samples.
Molecularly Imprinted Polymer-Based Optical Sensor for Isopropanol Vapor
Fabricated a MIP-based optical sensor for isopropanol vapor (a diabetes breath biomarker) with sensitivity up to 0.63 nm/%IPA and good selectivity among VOCs.
Molecularly imprinted polyvinylbenzoic acid based sensor for highly sensitive detection of acute lymphoblastic leukemia biomarker.
Created an electrochemical MIP sensor for the acute lymphoblastic leukemia biomarker PEP, with a detection limit of 1.56 × 10⁻¹³ M in human serum and high recovery rates (100.36–100.97%).
MIP-Based Impedimetric Sensor for Detecting Dengue Fever Biomarker.
Developed a MIP-based impedimetric sensor for the dengue NS1 protein, achieving a detection limit of 0.3 ng/mL and recoveries of 95–97% in human serum.
Molecularly imprinted polymers for biomarker detection: Advances in design, modeling, and sensing strategies
A review highlighting advances in MIP design (e.g., solid-phase synthesis, multi-template imprinting) and noting that challenges remain for clinical translation.
Recent advances in molecularly imprinted polymer-based electrochemical sensors
A review of MIP-based electrochemical sensors for disease biomarkers, covering nucleic acids, proteins, and small molecules, and discussing limitations for clinical use.
Target-Specific Electrochemical Sensing of Pipecolic Acid via Molecular Imprinting.
Developed an electrochemical MIP sensor for pipecolic acid (a neurological biomarker) with a detection limit of 1.05 µM, high selectivity, and stability over 28 days.
Electrochemically Synthesized MIP Sensors: Applications in Healthcare Diagnostics
A review of electrosynthesized MIP sensors for healthcare diagnostics, emphasizing their potential for commercial point-of-care devices.
Molecularly imprinted polymers for the detection of volatile biomarkers
A review of MIP sensors for volatile biomarkers (e.g., lung cancer), noting challenges in commercialization and the need for non-invasive breath analysis.
Rapid Detection of Amyloid β1-42 via PAMAM G4 Supported Molecularly Imprinted Sensor.
Developed a MIP sensor for amyloid β1-42 (Alzheimer's biomarker) with a detection limit of 0.14 ng/mL and minimal interference from Tau protein.